Peripheral T-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Peripheral T-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-11-13Clinical Trial Update: A Study to Evaluate Activity, Safety and Tolerability of ZX-101A in Relapsed/Refractory Hematological Malignancies [Phase 1, Phase 2]
Update on the completed Phase 1/2 study of ZX-101A assessing activity, safety, and tolerability in relapsed/refractory hematological maligna…
-
CLINICAL_TRIALS trial_result · 2024-10-29Clinical Trial Update: Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas [Phase 1, Phase 2]
Phase 1/2 trial updates show results for nivolumab plus standard-of-care chemotherapy in patients with Peripheral T-cell lymphoma, with the …
-
CLINICAL_TRIALS trial_result · 2024-09-27Clinical Trial Update: Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma"
This Clinical Trial Update reports results from a Special Drug Use Surveillance study of Brentuximab Vedotin IV in relapsed or refractory CD…
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) [Phase 2]
Phase 2 trial evaluating oral HBI-8000 in relapsed or refractory Peripheral T-Cell Lymphoma has completed, with efficacy and safety results …
-
CLINICAL_TRIALS trial_result · 2024-08-28Clinical Trial Update: AZD4573 as Monotherapy or in Combinations With Anti-cancer Agents in Patients With r/r PTCL or r/r cHL [Phase 2]
Phase 2 trial evaluating AZD4573 as monotherapy or in combination for relapsed/refractory peripheral T-cell lymphoma and relapsed/refractory…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-08-27Clinical Trial Update: Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas [Phase 1, Phase 2]
This clinical trial update covers a Phase 1/2 study of pembrolizumab plus pralatrexate in relapsed or refractory peripheral T-cell lymphomas…
-
CLINICAL_TRIALS trial_result · 2024-07-22Clinical Trial Update: Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01) [Phase 2]
Daiichi Sankyo reported an update on valemetostat tosylate (DS-3201b), an EZH1/2 dual inhibitor, in a Phase 2 trial (VALENTINE-PTCL01) for r…
-
CLINICAL_TRIALS trial_result · 2024-07-18Clinical Trial Update: Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab [Phase 2]
Phase 2 trial evaluating letermovir for prevention of cytomegalovirus reactivation in patients with hematologic malignancies treated with al…
-
CLINICAL_TRIALS trial_result · 2024-07-16Clinical Trial Update: Avelumab in Relapsed and Refractory Peripheral T-cell Lymphoma [Phase 2]
Avelumab was studied in a Phase 2 trial for relapsed or refractory peripheral T-cell lymphoma, and the results have been posted.
-
CLINICAL_TRIALS trial_result · 2024-07-09Clinical Trial Update: Toripalimab Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-Cell Lymphoma [Phase 2]
A Phase 2 trial evaluating toripalimab plus chidamide for relapsed/refractory peripheral T-cell lymphoma is currently active but not recruit…
-
CLINICAL_TRIALS trial_result · 2024-06-26Clinical Trial Update: Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard Therapy [Phase 2]
Phase 2 clinical trial results for tipifarnib in relapsed or refractory peripheral T-cell lymphoma have been posted.
-
CLINICAL_TRIALS trial_result · 2024-06-17Clinical Trial Update: Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL) [Phase 2]
Phase 2 study evaluating mogamulizumab (KW-0761) in previously treated peripheral T-cell lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2024-06-11Clinical Trial Update: A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) [Phase 2]
Phase 2 study results of Brentuximab Vedotin in Hodgkin lymphoma and CD30-expressing peripheral T-cell lymphoma have been completed. The res…
-
CLINICAL_TRIALS trial_result · 2024-05-16Clinical Trial Update: Minimal Residual Disease in Peripheral T-cell Lymphoma
This clinical trials update reports on minimal residual disease in peripheral T-cell lymphoma; the study has completed and is sponsored by W…
-
CLINICAL_TRIALS trial_result · 2024-04-10Clinical Trial Update: Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma [Phase 2]
Phase 2 trial evaluating the combination of romidepsin and lenalidomide in previously untreated peripheral T-cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2024-04-09Clinical Trial Update: Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma [Phase 3]
A Phase 3 clinical trial is investigating tucidinostat plus azacitidine and CHOP versus CHOP alone in untreated peripheral T-cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2024-01-26Clinical Trial Update: A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) [Phase 2]
Phase 2 study of SP-02L in relapsed or refractory Peripheral T-cell Lymphoma has completed; results posted in 2024.
-
CLINICAL_TRIALS trial_result · 2023-10-16Clinical Trial Update: Phase I/II Study of Linperlisib Plus Chidamide for R/R Peripheral T-cell Lymphoma: a Prospective, Multi-center Study [Phase 1, Phase 2]
A Phase 1/2 prospective, multi-center study evaluating linperlisib in combination with chidamide for relapsed/refractory peripheral T-cell l…
-
CLINICAL_TRIALS trial_result · 2023-10-13Clinical Trial Update: A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma [Phase 2]
A Phase 2 trial evaluating retreatment with brentuximab vedotin in classic Hodgkin lymphoma and CD30-expressing peripheral T-cell lymphoma h…
-
CLINICAL_TRIALS trial_result · 2023-08-04Clinical Trial Update: Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL) [Phase 2]
A Phase 2 prospective, single-arm, single-center clinical trial evaluating duvelisib in combination with chidamide for newly diagnosed perip…
-
CLINICAL_TRIALS trial_result · 2023-08-03Clinical Trial Update: An Open, Single Center, Non-randomized, Single Arm Clinical Study of Evaluating the Efficacy of Selinexor in the Maintenance Treatment of PTCL [Phase 2, Phase 3]
Open-label, single-center, non-randomized study evaluating selinexor as maintenance therapy in patients with peripheral T-cell lymphoma who …
-
CLINICAL_TRIALS trial_result · 2023-07-27Clinical Trial Update: A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma [Phase 1]
Phase 1 trial evaluating temsirolimus with etoposide and cyclophosphamide in children with relapsed acute lymphoblastic leukemia and non-Hod…
-
CLINICAL_TRIALS trial_result · 2023-07-05Clinical Trial Update: A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL [Phase 3]
A Phase 3 randomized trial comparing Chi-BEAM with BEAM + autologous stem cell transplant for newly diagnosed peripheral T-cell lymphoma is …
-
CLINICAL_TRIALS trial_result · 2023-06-13Clinical Trial Update: Targeted Drug Combined With CHOP in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma [Phase 2]
Phase 2 trial investigating a targeted drug combined with CHOP for newly diagnosed peripheral T-cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2023-06-07Clinical Trial Update: A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors [Phase 1, Phase 2]
Phase 1/2 clinical trial update for ASN002 in relapsed/refractory lymphoma and advanced solid tumors; the study status is TERMINATED with re…